Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

month observed survival advantage for the OGX-011/ TV-1011 arm.

OGX-011/ TV-1011 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and this SATURN trial is being conducted through the Special Protocol Assessment (SPA) process. Earlier this year, the European Medicines Agency indicated that the Committee for Medicinal Products for Human Use was in overall agreement with the company's development plan for OGX-011/ TV-1011 which included this Phase 3 trial.

In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize OGX-011/TV-1011. In addition to the ongoing SATURN trial assessing durable pain palliation as the primary endpoint for second-line chemotherapy in men with metastatic CRPC, the global Phase 3 clinical program also includes a Phase 3 trial in first-line chemotherapy for metastatic CRPC which assesses survival as the primary endpoint. A Phase 3 trial assessing survival as the primary endpoint in first-line treatment of advanced, unresectable non-small cell lung cancer (NSCLC) is also planned as part of the strategy to develop and commercialize OGX-011/TV-1011.

About Prostate Cancer

The National Cancer Institute reports that in 2009, approximately 192,280 new cases of prostate cancer will be diagnosed in the U.S. As the most frequently diagnosed cancer among men, one in six men will be diagnosed with prostate cancer during their lifetime. It is estimated that in 2009 in the U.S., 27,360 deaths will result due to the disease. The International Agency for Research on Cancer recently published estimates of cancer incidence and mortality in Europe in 2008. They reported 382,300 new cases of prostate cancer and 89,300 deaths related to prostate cancer.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Cloud ... drug design and development, announced today the expansion ... company has been granted supercomputing time at Argonne ... targets.  Through a discretionary allocation ... Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... CAMBRIDGE, Mass. , July 14, 2014 ... in the development of new therapies to treat neuropsychiatric ... Ahlholm has been appointed vice president of finance ... Mr. Ahlholm is a senior executive with more ... functions at technology and life science companies. His background ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... registry platform, announced that three PatientCrossroads-based patient ... the Phelan-McDermid Syndrome International Registry; and the ... been awarded contracts by the Patient-Centered Outcomes ... creation of a new health data network ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Md., Aug. 30 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Germany on Wednesday,September 5, 2007 at 9:50am Eastern ...
... Aug. 29 Sucampo,Pharmaceuticals, Inc. (Nasdaq: SCMP ) ... have exercised in full their option to,purchase 562,500 shares ... that the closing of that purchase took place on ... closing were sold by a selling,stockholder and Sucampo did ...
... Mass., Aug. 29 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... presentation,at the Thomas Weisel Partners 2007 Healthcare ... accessed by visiting the Investors section of ... http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ) The presentation ...
Cached Biology Technology:Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2Sucampo Pharmaceuticals Announces Exercise and Closing of IPO Over-Allotment Option 2Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation 2
(Date:7/14/2014)... the discovery and description of Rhipidocyrtus muiri - ... out to represent a new genus and species. The long ... Borneo is discussed in a recent paper published in the ... holotype male, and only known specimen of Rhipidocyrtus muiri ... to this it was transferred among several researchers in the ...
(Date:7/14/2014)... in the local environment manage much better in the ... environments. , A world without bees would be ... an additional 600 million to 1 billion Danish kroner ... bees making honey and pollinating a wide range of ... bees all over the world are under pressure from ...
(Date:7/14/2014)... Roquin protein, discovered in 2005, controls T-cell activation ... mRNAs. In doing so, it helps to guarantee ... body,s own structures that can lead to autoimmune ... diseases affect between five and ten per cent ... result of complex environmental influences when a genetic ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Best for bees to be stay-at-homes 2Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2
... Boston University have taught bacteria how to count. Professor ... sequence of genes that allow the microbes to count ... potential applications, which could include drug delivery and sensing ... application still to be addressed within synthetic biology: Can ...
... Each year the American Institute of Biological ... outstanding contributions to the biological sciences. Since ... annually to individuals who have made significant scientific ... fields of integrative and organismal biology. The ...
... Ludwig Institute for Cancer Research at the University of ... remarkable property of the contractile ring, a structure required ... works to divide the cell may facilitate development of ... The researchers show that even though both ...
Cached Biology News:Boston University biomedical engineers teach bacteria to count 2Boston University biomedical engineers teach bacteria to count 3Two Central High (Philadelphia) grads honored by AIBS 2Study may aid efforts to prevent uncontrolled cell division in cancer 2
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Upright Freezer Inventory Storage Racks for ... available to fit all makes and ... Made of high quality stainless ... high fiberboard, stainless steel or plastic ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Biology Products: